Noah S Philip1, S Louisa Carpenter2, Samuel J Ridout3, George Sanchez2, Sarah E Albright2, Audrey R Tyrka3, Lawrence H Price3, Linda L Carpenter3. 1. Center for Neurorestoration and Neurotechnology, Providence VA Medical Center, Providence, RI, United States; Butler Hospital Mood Disorders Research Program, Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, United States. Electronic address: Noah_Philip@Brown.edu. 2. Center for Neurorestoration and Neurotechnology, Providence VA Medical Center, Providence, RI, United States. 3. Butler Hospital Mood Disorders Research Program, Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, United States.
Abstract
BACKGROUND: Repetitive transcranial magnetic stimulation (rTMS) to left prefrontal cortex at 10Hz is the most commonly utilized protocol for major depressive disorder (MDD). Published data suggests that left sided 5Hz rTMS may be efficacious and well tolerated. OBJECTIVE: We analyzed outcomes in a naturalistic cohort of MDD patients who could not tolerate 10Hz rTMS and were routinely switched to 5Hz. We hypothesized that the efficacy of 5Hz rTMS would be equivalent to 10Hz. METHODS: Records were reviewed for patients (n=98) who received 15 or more acute rTMS treatments. The sample was split based upon the frequency (10 or 5Hz) at which the majority of treatments were delivered. The Inventory of Depressive Symptoms (IDS-SR) and 9-Item Patient Health Questionnaire (PHQ-9) were used to evaluate outcomes. RESULTS: Baseline IDS-SR was higher in the 5Hz (n=27) than in the 10Hz (n=71) group (p<.05), as was frequency of comorbid anxiety (p=.002). Depression outcomes did not differ between groups, and there were no differences in response or remission rates (all p>.1). Statistical power was sufficient to detect small group differences (d=.26). LIMITATIONS: Open-label data in a naturalistic setting. CONCLUSION: Outcomes associated with 5Hz rTMS did not differ from 10Hz, despite higher baseline depressive symptom severity and anxiety in 5Hz patients. 5Hz stimulation may be an alternative treatment option for patients unable to tolerate 10Hz rTMS. Published by Elsevier B.V.
BACKGROUND: Repetitive transcranial magnetic stimulation (rTMS) to left prefrontal cortex at 10Hz is the most commonly utilized protocol for major depressive disorder (MDD). Published data suggests that left sided 5Hz rTMS may be efficacious and well tolerated. OBJECTIVE: We analyzed outcomes in a naturalistic cohort of MDDpatients who could not tolerate 10Hz rTMS and were routinely switched to 5Hz. We hypothesized that the efficacy of 5Hz rTMS would be equivalent to 10Hz. METHODS: Records were reviewed for patients (n=98) who received 15 or more acute rTMS treatments. The sample was split based upon the frequency (10 or 5Hz) at which the majority of treatments were delivered. The Inventory of Depressive Symptoms (IDS-SR) and 9-Item Patient Health Questionnaire (PHQ-9) were used to evaluate outcomes. RESULTS: Baseline IDS-SR was higher in the 5Hz (n=27) than in the 10Hz (n=71) group (p<.05), as was frequency of comorbid anxiety (p=.002). Depression outcomes did not differ between groups, and there were no differences in response or remission rates (all p>.1). Statistical power was sufficient to detect small group differences (d=.26). LIMITATIONS: Open-label data in a naturalistic setting. CONCLUSION: Outcomes associated with 5Hz rTMS did not differ from 10Hz, despite higher baseline depressive symptom severity and anxiety in 5Hzpatients. 5Hz stimulation may be an alternative treatment option for patients unable to tolerate 10Hz rTMS. Published by Elsevier B.V.
Entities:
Keywords:
Anxiety; Major depression; Repetitive transcranial magnetic stimulation
Authors: Demetrio Ortega Rumi; Wagner F Gattaz; Sergio Paulo Rigonatti; Moacyr Alexandro Rosa; Felipe Fregni; Marina Odebrecht Rosa; Carlos Mansur; Martin Luiz Myczkowski; Ricardo Alberto Moreno; Marco Antonio Marcolin Journal: Biol Psychiatry Date: 2005-01-15 Impact factor: 13.382
Authors: Linda L Carpenter; Philip G Janicak; Scott T Aaronson; Terrence Boyadjis; David G Brock; Ian A Cook; David L Dunner; Karl Lanocha; H Brent Solvason; Mark A Demitrack Journal: Depress Anxiety Date: 2012-06-11 Impact factor: 6.505
Authors: M S George; Z Nahas; M Molloy; A M Speer; N C Oliver; X B Li; G W Arana; S C Risch; J C Ballenger Journal: Biol Psychiatry Date: 2000-11-15 Impact factor: 13.382
Authors: G E Bruder; R Fong; C E Tenke; P Leite; J P Towey; J E Stewart; P J McGrath; F M Quitkin Journal: Biol Psychiatry Date: 1997-05-01 Impact factor: 13.382
Authors: Christine A Conelea; Noah S Philip; Agustin G Yip; Jennifer L Barnes; Matthew J Niedzwiecki; Benjamin D Greenberg; Audrey R Tyrka; Linda L Carpenter Journal: J Affect Disord Date: 2017-03-29 Impact factor: 4.839
Authors: Noah S Philip; Jennifer Barredo; Mascha van 't Wout-Frank; Audrey R Tyrka; Lawrence H Price; Linda L Carpenter Journal: Biol Psychiatry Date: 2017-08-08 Impact factor: 13.382
Authors: Simone Rossi; Andrea Antal; Sven Bestmann; Marom Bikson; Carmen Brewer; Jürgen Brockmöller; Linda L Carpenter; Massimo Cincotta; Robert Chen; Jeff D Daskalakis; Vincenzo Di Lazzaro; Michael D Fox; Mark S George; Donald Gilbert; Vasilios K Kimiskidis; Giacomo Koch; Risto J Ilmoniemi; Jean Pascal Lefaucheur; Letizia Leocani; Sarah H Lisanby; Carlo Miniussi; Frank Padberg; Alvaro Pascual-Leone; Walter Paulus; Angel V Peterchev; Angelo Quartarone; Alexander Rotenberg; John Rothwell; Paolo M Rossini; Emiliano Santarnecchi; Mouhsin M Shafi; Hartwig R Siebner; Yoshikatzu Ugawa; Eric M Wassermann; Abraham Zangen; Ulf Ziemann; Mark Hallett Journal: Clin Neurophysiol Date: 2020-10-24 Impact factor: 4.861